{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:53:28Z","timestamp":1793332408269,"version":"4.5.0"},"reference-count":39,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2021,8,1]]},"DOI":"10.1001\/jamainternmed.2021.2738","type":"journal-article","created":{"date-parts":[[2021,5,16]],"date-time":"2021-05-16T14:30:36Z","timestamp":1621175436000},"page":"1071","source":"Crossref","is-referenced-by-count":70,"title":["Longitudinal Assessment of Safety of Femoropopliteal Endovascular Treatment With Paclitaxel-Coated Devices Among Medicare Beneficiaries"],"prefix":"10.1001","volume":"181","author":[{"given":"Eric A.","family":"Secemsky","sequence":"first","affiliation":[{"name":"Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyu","family":"Shen","sequence":"additional","affiliation":[{"name":"Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Schermerhorn","sequence":"additional","affiliation":[{"name":"Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Vascular and Endovascular Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Yeh","sequence":"additional","affiliation":[{"name":"Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"11","key":"ioi210028r1","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.jacc.2016.11.008","article-title":"2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.","volume":"69","author":"Gerhard-Herman","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"ioi210028r2","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jvs.2019.05.034","article-title":"Nationwide trends in drug-coated balloon and drug-eluting stent utilization in the femoropopliteal arteries.","volume":"71","author":"Mohapatra","year":"2020","journal-title":"J Vasc Surg"},{"issue":"15","key":"ioi210028r3","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.115.016900","article-title":"Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial.","volume":"133","author":"Dake","year":"2016","journal-title":"Circulation"},{"issue":"6","key":"ioi210028r4","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.118.007702","article-title":"Long-term clinical effectiveness of a drug-coated balloon for the treatment of femoropopliteal lesions.","volume":"12","author":"Laird","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"issue":"1","key":"ioi210028r5","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/ccd.v92.1","article-title":"SCAI consensus guidelines for device selection in femoral-popliteal arterial interventions.","volume":"92","author":"Feldman","year":"2018","journal-title":"Catheter Cardiovasc Interv"},{"issue":"24","key":"ioi210028r6","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011245","article-title":"Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials.","volume":"7","author":"Katsanos","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"ioi210028r8","first-page":"18","article-title":"The market reacts quickly: changes in paclitaxel vascular device purchasing within the Ascension Healthcare System.","volume":"32","author":"Monteleone","year":"2020","journal-title":"J Invasive Cardiol"},{"issue":"20","key":"ioi210028r11","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1016\/j.jacc.2019.01.013","article-title":"Mortality not correlated with paclitaxel exposure: an independent patient-level meta-analysis of a drug-coated balloon.","volume":"73","author":"Schneider","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"ioi210028r14","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.ahj.2010.07.038","article-title":"Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions.","volume":"160","author":"Mauri","year":"2010","journal-title":"Am Heart J"},{"issue":"23","key":"ioi210028r15","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"ioi210028r18","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1001\/jamacardio.2019.0325","article-title":"Association of survival with femoropopliteal artery revascularization with drug-coated devices.","volume":"4","author":"Secemsky","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"20","key":"ioi210028r19","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1016\/j.jacc.2019.02.020","article-title":"Drug-eluting stent implantation and long-term survival following peripheral artery revascularization.","volume":"73","author":"Secemsky","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"ioi210028r20","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.120.007040","article-title":"Rationale and design of the SAFE-PAD study.","volume":"14","author":"Secemsky","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"2","key":"ioi210028r21","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.jvs.2017.10.090","article-title":"Regional variation in racial disparities among patients with peripheral artery disease.","volume":"68","author":"O\u2019Donnell","year":"2018","journal-title":"J Vasc Surg"},{"issue":"1","key":"ioi210028r23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/0962280211403597","article-title":"On weighting approaches for missing data.","volume":"22","author":"Li","year":"2013","journal-title":"Stat Methods Med Res"},{"issue":"20","key":"ioi210028r24","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Adjusted Kaplan-Meier estimator and log-rank test with inverse probability of treatment weighting for survival data.","volume":"24","author":"Xie","year":"2005","journal-title":"Stat Med"},{"issue":"6","key":"ioi210028r25","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1080\/03610910902859574","article-title":"Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research.","volume":"38","author":"Austin","year":"2009","journal-title":"Commun Stat Simul Comput"},{"issue":"24","key":"ioi210028r26","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1002\/sim.v39.24","article-title":"Sensitivity analysis of treatment effect to unmeasured confounding in observational studies with survival and competing risks outcomes.","volume":"39","author":"Huang","year":"2020","journal-title":"Stat Med"},{"issue":"22","key":"ioi210028r27","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1016\/j.jacc.2013.07.036","article-title":"Comparison of transradial versus transfemoral percutaneous coronary intervention in routine practice: evidence for the importance of \u201cfalsification hypotheses\u201d in observational studies of comparative effectiveness.","volume":"62","author":"Wimmer","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"27","key":"ioi210028r28","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1002\/sim.v36.27","article-title":"Practical recommendations for reporting Fine-Gray model analyses for competing risk data.","volume":"36","author":"Austin","year":"2017","journal-title":"Stat Med"},{"issue":"23","key":"ioi210028r29","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1161\/CIRCULATIONAHA.119.044697","article-title":"Mortality and paclitaxel-coated devices: an individual patient data meta-analysis.","volume":"141","author":"Rocha-Singh","year":"2020","journal-title":"Circulation"},{"issue":"1","key":"ioi210028r30","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.jvs.2020.07.093","article-title":"Update on paclitaxel for femoral-popliteal occlusive disease in the 15 months following a summary level meta-analysis demonstrated increased risk of late mortality and dose response to paclitaxel.","volume":"73","author":"Schneider","year":"2021","journal-title":"J Vasc Surg"},{"issue":"5","key":"ioi210028r33","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1583\/11-3560.1","article-title":"Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study.","volume":"18","author":"Dake","year":"2011","journal-title":"J Endovasc Ther"},{"issue":"5","key":"ioi210028r34","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1161\/CIRCULATIONAHA.114.011004","article-title":"Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial.","volume":"131","author":"Tepe","year":"2015","journal-title":"Circulation"},{"issue":"2","key":"ioi210028r35","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJMoa1406235","article-title":"Trial of a paclitaxel-coated balloon for femoropopliteal artery disease.","volume":"373","author":"Rosenfield","year":"2015","journal-title":"N Engl J Med"},{"issue":"26","key":"ioi210028r36","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1056\/NEJMoa2005206","article-title":"Mortality with paclitaxel-coated devices in peripheral artery disease.","volume":"383","author":"Nordanstig","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"ioi210028r37","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.jcin.2020.10.028","article-title":"Acute kidney injury following in-patient lower extremity vascular intervention: from the National Cardiovascular Data Registry.","volume":"14","author":"Safley","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"issue":"12","key":"ioi210028r38","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.jcin.2019.03.012","article-title":"Bleeding complications in lower-extremity peripheral vascular interventions: insights from the NCDR PVI Registry.","volume":"12","author":"Bhardwaj","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"issue":"14","key":"ioi210028r39","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1161\/CIRCULATIONAHA.119.040518","article-title":"Mortality assessment of paclitaxel-coated balloons: patient-level meta-analysis of the ILLUMENATE Clinical Program at 3 years.","volume":"140","author":"Gray","year":"2019","journal-title":"Circulation"},{"key":"ioi210028r17","year":"2015"},{"key":"ioi210028r7","unstructured":"McKeown? LA. Two trials halted in wake of study linking paclitaxel-coated devices to deaths in PAD. Accessed April 19, 2021. https:\/\/www.tctmd.com\/news\/two-trials-halted-wake-study-linking-paclitaxel-coated-devices-deaths-pad"},{"key":"ioi210028r9","unstructured":"US Food & Drug Administration. Treatment of peripheral arterial disease with paclitaxel-coated balloons and paclitaxel-eluting stents potentially associated with increased mortality\u2014letter to health care providers. Published January 17, 2019. Accessed January 21, 2019. https:\/\/www.fda.gov\/medical-devices\/letters-health-care-providers\/treatment-peripheral-arterial-disease-paclitaxel-coated-balloons-and-paclitaxel-eluting-stents"},{"key":"ioi210028r10","unstructured":"US Food & Drug Administration. Update: treatment of peripheral arterial disease with paclitaxel-coated balloons and paclitaxel-eluting stents potentially associated with increased mortality\u2014letter to health care providers. Published March 15, 2019. Accessed March 26, 2019. https:\/\/www.fda.gov\/medical-devices\/letters-health-care-providers\/update-treatment-peripheral-arterial-disease-paclitaxel-coated-balloons-and-paclitaxel-eluting"},{"key":"ioi210028r12","unstructured":"US Food & Drug Administration. FDA executive summary: Circulatory System Devices Panel Meeting: June 19 and 20, 2019. General Issues Panel. Paclitaxel-Coated Drug Coated Balloon and Drug-Eluting Stent Late Mortality Panel. Accessed March 21, 2020. https:\/\/www.fda.gov\/media\/127698\/download"},{"key":"ioi210028r13","unstructured":"US Food & Drug Administration. Update: treatment of peripheral arterial disease with paclitaxel-coated balloons and paclitaxel-eluting stents potentially associated with increased mortality. Published August 7, 2019. Accessed October 15, 2019. https:\/\/www.fda.gov\/medical-devices\/letters-health-care-providers\/august-7-2019-update-treatment-peripheral-arterial-disease-paclitaxel-coated-balloons-and-paclitaxel"},{"key":"ioi210028r16","unstructured":"US Food & Drug Administration. Paclitaxel-Coated Drug-Coated Balloon (DCB) and Drug-Eluting Stent (DES) Late Mortality Panel, Circulatory System Devices Panel Meeting: General Issues Meeting. Day two (45 min), June 20, 2019. Accessed March 21, 2020. https:\/\/www.fda.gov\/media\/128314\/download"},{"key":"ioi210028r22","unstructured":"Centers for Medicare & Medicaid Services. Chronic Conditions Data Warehouse. Accessed October 26, 2020. https:\/\/www2.ccwdata.org\/web\/guest\/condition-categories"},{"key":"ioi210028r31","unstructured":"US Food & Drug Administration. Use of real-world evidence to support regulatory decision-making for medical devices: guidance for industry and Food and Drug Administration staff. Published August 31, 2017. Accessed November 9, 2020. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/use-real-world-evidence-support-regulatory-decision-making-medical-devices"},{"key":"ioi210028r32","unstructured":"Research Data Assistance Center. Death information in the research identifiable Medicare data. Published July 11, 2018. Accessed November 9, 2020. https:\/\/resdac.org\/articles\/death-information-research-identifiable-medicare-data"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2780092\/jamainternal_secemsky_2021_oi_210028_1627674956.15956.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T13:05:58Z","timestamp":1627909558000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2780092"}},"subtitle":["The SAFE-PAD Study"],"short-title":[],"issued":{"date-parts":[[2021,8,1]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2021.2738","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8,1]]}}}